Pfizer

U.S. stocks were little moved to start off the month of May as investors and traders are cautious before April's nonfarm payrolls report are released on Friday. The consensus estimate for Friday's figure stands at 215,000 which would trump March's 192,000 number. “This is a really important...

The “on-again-off-again” courtship of British pharma AstraZeneca (NYSE: AZN) by U.S. drugmaker, Pfizer (NYSE: PFE), was on again, according to a statement from Pfizer. The renewed offer of almost $100 billion may, according to analysts, go over that amount. AstraZeneca rebuffed Pfizer’s $98.9...

This weekend in Barron's online: the Barron's Big Money poll, as well as the prospects for AIG, Pfizer, Tullow, Trinity Biotech and more. Cover Story "U.S. Money Managers Are Cautiously Optimistic" by Jack Willoughby. Barron's Big Money poll reveals that fewer money managers are bullish. But...

Like Big Oil, Big Pharma has entered a period of consolidation. There are many factors contributing to this. First, it can be cheaper to buy a company with a promising product rather than undergo the costs of developing a drug. Add in low interest rates that make it cheap to borrow money to...

U.S. stocks inched higher as Apple's strong earnings reported on Wednesday proved to be not enough to ease fears over an escalating tension between Russia and Ukraine. Reports surfaced of escalated troop movements in Ukraine while Russia began military drills near the Ukraine border. After...

U.S. stocks rose as investors felt that earnings season is positive enough so far to reverse weakness the markets have seen in recent weeks. "Investors were braced for poor results, and at least so far, the numbers have been better than feared. We'll have a little more information to act on...

According to Reuters, big pharma giant, Pfizer (NYSE: PFE) is considering a $100 billion bid for overseas rival AstraZeneca (NYSE: AZN). Reuters gives credit to Britain’s Sunday Times that cited  senior investment bankers who said that conversations between the two companies had taken place...

U.S. stocks rose to start off the holiday-filled shortened trading week on a positive note as investors found plenty of reason to be optimistic on retail sales which jumped the most since 2012. Investors were also encouraged by Citigroup's better than expected earnings which eased investor...

U.S. stocks declined for the third straight day in another trading session in which Internet, social media, biotechnology and momentum stocks sold off. The Dow suffered another triple-digit point loss while the three major indices each saw declines greater than one percent. The timing of the...

U.S. stocks declined as concerns escalated over Ukraine, two days before its citizens will vote in a referendum to split from Ukraine and become part of Russia. Russian President Vladimir Putin is gearing up to “invade eastern Ukraine” as a six hour talk between U.S. Secretary of State John...

In the pharmaceutical and biotech space, giant moves in a company’s stock isn’t exactly news and in this case a decline of 1.4 percent shouldn’t be much of a story...but when the company is Pfizer (NYSE: PFE), a 1.4 percent loss means something big probably happened. And it did. Wednesday, a U....

U.S. stocks were little changed as investors found no new positive (or negative) developments from Ukraine and no new economic reports from China. Stanley Fischer, the nominee for Federal Reserve vice chairman will deliver a prepared testimony ahead of his confirmation at the Senate Banking...

Short interest in most of the leading biotech and emerging pharmaceutical companies declined between the February 14 and February 28 settlement dates. But Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) bucked that trend. Short interest in Gilead...

The new year has proved to be a volatile one on the stock markets. After seeing a sizable correction in January, the S&P 500 and Dow Jones Industrial Average (DJIA) are again hitting or near all-time highs. Here is a quick look at the five top-performing Dow stocks in the past month. Note...

Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...